GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cryosite Ltd (ASX:CTE) » Definitions » Valuation Rank

Cryosite (ASX:CTE) Valuation Rank


View and export this data going back to 2002. Start your Free Trial

What is Cryosite Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Cryosite Valuation Rank Related Terms

Thank you for viewing the detailed overview of Cryosite's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Cryosite Business Description

Traded in Other Exchanges
N/A
Address
13a Ferndell Street, South Granville, Sydney, NSW, AUS, 2142
Cryosite Ltd is engaged in the provision of supply chain logistics, and management of pharmaceutical products used in clinical trials. The company's operating segment includes Cord Blood and Tissue Storage and Clinical Trials and Biological Services Logistics. It generates maximum revenue from the Clinical Trials and Biological Services Logistics segment. The clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labeling, status management, secondary packaging, scheduled drug distribution, destruction, returns, and biological services.